New Climate Strategy
BeiGene will set a quantitative Scope 1 and 2 emissions goal by 2024 and plans to set a quantitative Scope 3 emissions goal by 2025. In 2022, we are building a strategic roadmap that includes energy efficiency projects and renewable energy purchases. We will begin conducting energy audits in our R&D and manufacturing facilities, which account for the majority of our Scope 1 and 2 emissions. We are also assessing how to best reduce GHG emissions across our value chain.
Our ability to rapidly develop and commercialize new medicines is helping us bring innovative, life-saving medicines to millions more patients globally. To meet the growing demand for our medicines, we are investing in additional laboratory space and manufacturing capacity, resulting in increased GHG emissions, water use, and waste creation. While our overall resource use is projected to increase, we are working to improve our efficiency, producing more product with fewer inputs per batch.
I entered the EHS field because of the important role it plays in protecting the environment, the health and safety of my colleagues, and the communities where we work. This year, I helped our Guangzhou and Suzhou manufacturing facilities achieve ISO 14001 certification for environmental management systems and ISO 45001 certification for occupational health and safety. I really appreciate ISO’s focus on continuous improvement and how it actively engages employees in that process. By applying the core principle of PDCA (Plan-Do-Check-Adjust), we are building our colleagues’ awareness, knowledge, and skills to drive an EHS culture where they take ownership of our performance and are empowered to make improvements.
Leo Li, Head of EHS
- Set a quantitative Scopes 1 and 2 emissions goal by 2024
- Set a quantitative Scope 3 target by 2025. To advance this goal, we will engage with two-thirds of our raw material supplier base (using 2021 spend information)